Exhibit 99.1

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

As at and for the three and six months ended June 30, 2026 and 2025

(Unaudited - expressed in U.S. Dollars)

XORTX THERAPEUTICS INC.

Condensed Interim Consolidated Statements of Financial Position

(Unaudited - expressed in U.S. Dollars)

Nature of operations and going concern (Note 1)

Commitments (Note 15)

Subsequent event (Note 17)

XORTX THERAPEUTICS INC.

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

For the three and six months ended June 30, 2026 and 2025

(Unaudited - expressed in U.S. Dollars)

XORTX THERAPEUTICS INC.

Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity

(Unaudited - expressed in U.S. Dollars)

The shares outstanding presented have been adjusted to reflect the effect of the 5:1 share consolidation that took place on April 6, 2026. Common shares, options, warrants and per share amounts have been adjusted for the 5:1 share consolidation unless otherwise noted.

XORTX THERAPEUTICS INC.

Condensed Interim Consolidated Statements of Cash Flows

For the six months ended June 30, 2026 and 2025

(Unaudited - expressed in U.S. Dollars)

XORTX Therapeutics Inc. (the “Company” or “XORTX”) was incorporated under the laws of Alberta, Canada on August 24, 2012.

XORTX is a public company listed on the TSX Venture Exchange (the “TSXV”) and on the Nasdaq Stock Market (“Nasdaq”) under the symbol “XRTX”. The Company’s operations and mailing address is 3710 – 33^rd Street NW, Calgary, Alberta, Canada T2L 2M1 and its registered address is located at 250 Howe Street, 20th Floor, Vancouver, British Columbia, V6C 3R8.

XORTX is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy, and fatty liver disease. The Company’s current focus is on developing products to slow and/or reverse the progression of these diseases.

The Company is subject to a number of risks associated with the successful development of new products and their marketing and the conduct of its clinical studies and their results. The Company will have to finance its research and development activities and its clinical studies. To achieve the objectives in its business plan, the Company plans to raise the necessary capital and to generate revenues. Although there is no certainty, management is of the opinion that additional funding for future projects and operations can be raised as needed. The products developed by the Company will require approval from the U.S. Food and Drug Administration and equivalent organizations in other countries before their sale can be authorized. If the Company is unsuccessful in obtaining adequate financing in the future, research activities will be postponed until market conditions improve. These circumstances and conditions indicate the existence of a material uncertainty that casts significant doubt about the Company’s ability to continue as a going concern.

Statement of Compliance

These condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34 (IAS 34), Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). Accordingly, certain disclosures included in the annual financial statements prepared in accordance with IFRS Accounting Standards (“IFRS”) have been condensed or omitted. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2025.

Material accounting policies

These condensed interim consolidated financial statements have been prepared on a basis consistent with the material accounting policies disclosed in the annual financial statements for the year ended December 31, 2025.

Basis of Measurement and Presentation

These condensed interim consolidated financial statements have been prepared using the historical cost convention except for financial instruments which have been measured at fair value. These condensed interim consolidated financial statements were prepared on an accrual basis except for cash flow information.

These condensed interim consolidated financial statements incorporate the financial statements of the Company and its 100% owned subsidiary, XORTX Pharma Corp. The accounts of the Company’s subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated.

These condensed interim consolidated financial statements were approved for issue by the Board of Directors on August 13, 2026.

The preparation of condensed interim consolidated financial statements requires management to make judgments and estimates that affect the amounts reported in the condensed interim consolidated financial statements and notes. By their nature, these judgments and estimates are subject to change and the effect on the consolidated financial statements of changes in such judgments and estimates in future periods could be material. These judgments and estimates are based on historical experience, current and future economic conditions, and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results could differ from these judgments and estimates.

Revisions to accounting estimates are recognized in the period in which the estimate is revised and may affect both the period of revision and future periods. Information about critical accounting judgments in applying accounting policies that have the most significant risk of causing material adjustment to the carrying amounts of assets and liabilities recognized in the condensed interim consolidated financial statements within the next financial year are discussed below:

Share-based payment transactions and warrant liabilities

The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Warrant liabilities are accounted for as derivative liabilities if the proceeds from exercise are either not fixed, denominated in a currency other than the functional currency, or can be settled on a net basis, and therefore do not meet the fixed for fixed criteria. Estimating fair value for share-based transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the instrument. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the share option or warrant, volatility and dividend yield and making assumptions about them.

Classification of contract payments

In concluding that contract payments are a non-current asset, management considered when future regulatory and clinical trial programs are anticipated to be completed. Management assessed that the future regulatory and clinical trial programs would not be completed within 12 months from period end and therefore classified the contract payments as a non-current asset.

Impairment of intangible assets

Patents (obtained and pending) and licenses are reviewed for impairment at each financial reporting date. If, in the judgment of management, future economic benefits will not flow to the Company, then the Company will assess the recoverable value of the asset. If the carrying value is greater than the recoverable value, the asset will be impaired to the recoverable value.

Determination of functional currency

In concluding that the U.S. dollar is the functional currency of the Company and its subsidiary, management considered the currency that mainly influences the cost of providing goods and services in the primary economic environment in which each entity operates and the currency in which funds from financing are generated, or if there has been a change in events or conditions that determined the primary economic environment.

3.

Critical accounting judgments and estimates (continued)

Treatment of research and development costs

Costs to develop products are capitalized to the extent that the criteria for recognition as intangible assets in IAS 38 Intangible Assets are met. Those criteria require that the product is technically and economically viable, the Company has the intention and ability to use the asset, and how the asset will generate future benefits. Management assessed the capitalization of development costs based on the attributes of the development project, perceived user needs, industry trends and expected future economic conditions. Management considers these factors in aggregate and applies significant judgment to determine whether the product is feasible. The Company has not capitalized any development costs as at June 30, 2026.

Leases

Value of right-of-use assets and lease obligations require judgement in determining lease terms such as extension options, determining whether a lease contract contains an identified asset to which the Company has the right to use substantially all of the economic benefits from, and the incremental borrowing rate applied. The Company estimates the incremental borrowing rate based on the lease term, collateral assumptions and the economic environment in which the lease exists. Renewal options are only included if management is reasonably certain that the option will be renewed.

Classification of pre-funded warrants

Management applied judgment when determining the appropriate classification of pre-funded warrants included in unit offerings. Management considered the characteristics of derivative instruments and concluded that the pre-funded warrants should be classified as an equity instrument.

Current and deferred taxes

The measurement of income taxes payable and deferred income tax assets and liabilities requires management to make judgments in the interpretation and application of the relevant tax laws. Such differences may result in eventual tax payments differing from amounts accrued. Reported amounts for deferred tax assets and liabilities are based on management’s expectation for the timing and amounts of future taxable income or loss, as well as future taxation rates. Changes to these underlying estimates may result in changes to the carrying value, if any, of deferred income tax assets and liabilities.

Asset acquisition

Significant judgment is required in determining whether an acquired set of activities and assets meets the definition of a business under IFRS 3. In making this determination, management considers whether the acquired set includes substantive processes and the ability to generate outputs.

During the six months ended June 30, 2026, the Company acquired the VB4-P5 renal anti-fibrotic therapeutic program from Vectus Biosystems Limited. Management concluded that the transaction represented an asset acquisition rather than a business combination because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable intangible asset and the acquired set did not include substantive processes. Accordingly, the transaction was accounted for as an asset acquisition and directly attributable acquisition costs were capitalized as part of the cost of the acquired asset.

The Company’s cash consists of cash held and interest-bearing deposits with the Company’s bank and brokerage accounts. The current annual interest rate earned on these deposits is 3.35% (2025 – 2.10% to 3.50%).

The Company’s prepaid expenses relate to the following:

¹ Investor relations conferences and services primarily consist of a prepaid marketing and investor relations services agreement entered into on May 18, 2026 with IR Agency LLC. The agreement provides for marketing activities over a 90-day term. As at June 30, 2026, the remaining unamortized balance was $1,305,556 (December 31, 2025 - $nil).

During the year ended December 31, 2020, the Company entered into an agreement with Prevail InfoWorks Inc. As part of the agreement, the Company paid $1,200,000 through the issuance of units in the private placement that closed February 28, 2020, to be applied to future regulatory and clinical trial programs. The 108,590 units issued were measured by reference to their fair value on the issuance date, which is equal to CAD $14.76 per unit.

The Company’s intangible assets consists of (i) licensed intellectual property from various third parties and (ii) acquired intellectual property related to the VB4-P5 renal anti-fibrotic program. Licensed intellectual property is amortized over its estimated useful life. The acquired VB4-P5 intellectual property represents an in-process research asset. Due to its only recent acquisition, amortization was not recorded on this asset during the period ended June 30, 2026. The asset will be assessed for impairment whenever indicators of impairment exist and, at a minimum, annually.

Licensed intellectual property

Acquired VB4-P5 asset

On April 13, 2026, the Company completed the acquisition of the VB4-P5 renal anti-fibrotic therapeutic program from Vectus Biosystems Limited. The acquired assets include intellectual property rights related to the VB4-P5 compound, associated patent rights, regulatory documentation, manufacturing data and related development information. Management concluded that the transaction represented an asset acquisition rather than a business combination because substantially all of the fair value of the gross assets acquired did not include substantive processes.

Consideration for the acquisition consisted of 154,544 common shares and 692,150 pre-funded warrants exercisable at US$0.0001 per share. The acquisition consideration was measured based on the fair value of the equity instruments issued on the acquisition date. The pre-funded warrants contain provisions restricting exercise if such exercise would result in Vectus beneficially owning more than 9.99% of the Company’s issued and outstanding common shares and expire on April 13, 2031.

The Company recognized the acquired VB4-P5 intellectual property at a total cost of $2,342,619, consisting of $1,871,194 of acquisition consideration and $471,125 of directly attributable acquisition costs, of which $293,803 was deferred at December 31, 2025.

The Company entered into an office lease during the year ended December 31, 2022 for which a right-of-use asset was recognized (Note 11). During the year ended December 31, 2025, the Company extended its office lease. A $88,074 right-of-use asset addition was recognized with a corresponding $88,074 increase to the lease liability.

9.

Accounts payable and accrued liabilities

10.

Lease obligation

The Company has entered into an office lease expiring in 2026, with an imputed interest rate of 8% per annum. A reconciliation of the outstanding lease obligation as at June 30, 2026 is as follows:

The $88,074 lease obligation addition recognized in the year ended December 31, 2025 relates to an extension of the office lease to May 31, 2026.

The office lease expired on May 31, 2026. As at June 30, 2026, the Company had no remaining lease obligations and no future minimum lease payments.

The shares outstanding presented have been adjusted to reflect the effect of the 5:1 share consolidation that took place on April 6, 2026. Common shares, options and warrants and per share amounts have been adjusted for the 5:1 share consolidation unless otherwise noted.

11.

Share capital and reserves (continued)

c) Diluted Weighted Average Number of Common Shares Outstanding

During the six months ended June 30, 2026 and 2025, the Company had a net loss, as such, the diluted loss per share calculation excludes any potential conversion of options and warrants that would decrease loss per share.

A summary of the changes in warrants for the six months ended June 30, 2026 and the year ended December 31, 2025 is presented below:

At June 30, 2026, the weighted average contractual remaining life of the unexercised warrants was 2.94 years (December 31, 2025 – 2.58 years).

The following table summarizes information on warrants outstanding at June 30, 2026:

A summary of the changes in pre-funded warrants for the six months ended June 30, 2026 and the year ended December 31, 2025 is presented below:

A summary of the changes in finders’ and underwriters’ warrants for the six months ended June 30, 2026 and the year ended December 31, 2025 is presented below:

At June 30, 2026, the weighted average contractual remaining life of the unexercised finders’ and underwriters’ warrants was 1.21 years (December 31, 2025 – 1.64 years).

The following table summarizes information on finders’ and underwriters’ warrants outstanding at June 30, 2026:

The weighted average contractual remaining life of the unexercised options was 1.81 years (December 31, 2025 – 2.27 years).

The following table summarizes information on stock options outstanding at June 30, 2026:

⁽¹⁾ Expired unexercised subsequent to June 30, 2026

During the years ended December 31, 2024, 2022 and 2021, the Company issued warrants which were recorded as derivative financial liabilities as the exercise price was denominated in a currency other than the functional currency of the Company and in certain situations allow the holder to exercise the warrants on a cashless basis and therefore may be settled other than by the exchange of a fixed amount of cash. Under the cashless exercise option, the holders of these warrants may elect to settle the warrants on a cashless basis if the common shares are not subject to an effective registration statement at the time the holder wishes to exercise them. A contract that may be settled by a single net payment (generally referred to as net cash settled or net equity settled) is a financial liability and not an equity instrument.

These warrants are revalued at each reporting period and any gain or loss is recorded in profit or loss.

The balance of the derivative warrant liabilities (level 3) is as follows:

Significant assumptions used in determining the fair value of the derivative warrant liabilities at June 30, 2026 and December 31, 2025 are as follows:

The fair value is classified as level 3 as expected volatility is determined using historical volatility and is therefore not an observable input.

12.

Related party transactions

All related party transactions were measured at fair value. All amounts due from/payable to related parties are unsecured, non-interest bearing and have no fixed terms of repayment.

During the six months ended June 30, 2026 and 2025, the Company incurred the following transactions with related parties:

The Company’s financial instruments consist of cash, accounts receivable, contract payments, accounts payable and accrued liabilities, lease obligation and derivative warrant liability. The fair values of cash and accounts payable and accrued liabilities and lease liability approximate their carrying values at June 30, 2026, due to their short-term nature. Derivative warrant liability is carried at fair value and is classified within Level 3 of the fair value hierarchy.

The Company thoroughly examines the various financial instruments and risks to which it is exposed and assesses the impact and likelihood of those risks. These risks include foreign currency risk, interest rate risk, market risk, credit risk, and liquidity risk. Where material, these risks are reviewed and monitored by the Board of Directors

There have been no changes in any risk management policies since December 31, 2025.

The Company defines capital that it manages as shareholders’ equity. The Company manages its capital structure in order to have funds available to support its research and development and sustain the future development of the business. When managing capital, the Company’s objective is to ensure the entity continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders. Management adjusts the capital structure as necessary in order to support its activities.

Since inception, the Company’s objective in managing capital is to ensure sufficient liquidity to finance its research and development activities, general and administrative expenses, expenses associated with intellectual property protection, and its overall capital expenditures. There were no changes during the six months ended June 30, 2026. The Company is not exposed to external requirements by regulatory agencies regarding its capital.

The Company’s long-term arrangements that are not recognized as liabilities as at June 30, 2026 and December 31, 2025 are as follows:

The President, Co-CEO, and a director of the Company has a long-term employment agreement with the Company. The agreement has a termination clause whereby he is entitled to the equivalent of 12 times his then current monthly salary which, as of June 30, 2026 and December 31, 2025, equated to an annual salary of $321,000.

On June 6, 2026, the Company entered into a consulting agreement with a company controlled by its Co-Chief Executive Officer to provide executive management services. The agreement provides for annual consulting fees of $240,000 and is of indefinite duration, subject to termination by either party upon 90 days' written notice. The agreement contains a change-of-control provision whereby, if a change of control occurs and the consulting agreement is terminated by the Company without cause, or by the consultant for good reason, within 18 months of the change of control, the consultant is entitled to a lump-sum payment equal to 50% of the annual consulting fee plus the greater of the most recently earned annual bonus and the target annual bonus for the year in which the change of control occurs. In addition, any unvested stock options held by the consultant immediately vest upon a change of control

In the normal course of business, the Company has committed to payments totaling $318,821 (December 31, 2025 - $131,199) related to its clinical trial, and manufacturing, activities, and other regular business activities excluding management and director compensation which are expected to occur over the next 12 months.

16.

Segmented information

The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia related diseases. As the operations comprise a single reporting segment, amounts disclosed also represent segment amounts. All long-term assets of the Company are located in Canada.

On July 24, 2026, 86,000 pre-funded warrants were exercised yielding gross proceeds of $8.60.

On July 29, 2026, the Company announced the appointment of Depesh Narotam to its board of directors.

On July 31, 2026, the Company announced the resignation of its chairman, Anthony Giovinazzo.

20